Infectious Diseases (all articles) | Page 77 of 298 | Links Medicus Content Curation & Alerts in Medicine

IDSA Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19.

11 Nov, 2021 | 09:01h | UTC

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

Commentary on Twitter

New recommendation on the use of eye protection as well as revised recommendations and literature on the use of PPE now available in IDSA’s COVID-19 Infection Prevention Guideline: https://t.co/MiACvSoG92 #COVID19Guidelines pic.twitter.com/Zp7s0Ely9J

— IDSA (@IDSAInfo) November 5, 2021

Podcast | COVID Updates: The Outpatient Edition.

11 Nov, 2021 | 08:57h | UTC

COVID Updates: The Outpatient Edition – The Curbsiders

Commentary on Twitter

Who gets a #COVID booster? Can we mix & match vaccines? What are monoclonal antibodies & when should we use them? Shots for kids? Ready yourself to answer these questions & more w/ @MonicaGandhi9 #vaccine #MedEd #FOAMed https://t.co/URrfwtuxVf pic.twitter.com/o26ElbPNaJ

— The Curbsiders (@thecurbsiders) November 8, 2021

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.

11 Nov, 2021 | 08:53h | UTC

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

Perspective | COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed.

11 Nov, 2021 | 08:55h | UTC

COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

11 Nov, 2021 | 08:52h | UTC

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

RCT: Pfizer vaccine shows 90.7% efficacy for preventing Covid-19 in children 5 to 11 years of age.

10 Nov, 2021 | 07:24h | UTC

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

Commentary on Twitter

In this multi-phase trial, two 10-μg doses of the BNT162b2 vaccine administered 21 days apart were safe, immunogenic, and 90.7% effective against #COVID19 in 5-to-11-year-old children. #Covid19vaccine https://t.co/kuj2eI4YCE pic.twitter.com/BWEkYxn8a0

— NEJM (@NEJM) November 9, 2021

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic.

10 Nov, 2021 | 07:22h | UTC

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic – The Lancet

Commentary on Twitter

NEW—How an outbreak became a pandemic: an analysis of the early months of #COVID19 by @TheIndPanel.

Authors point to reform & offer a framework for robust future #pandemic preparedness & response. https://t.co/MlW6zXj2Dn @sudhvir pic.twitter.com/rgHu1QggNQ

— The Lancet (@TheLancet) November 9, 2021

French health authority advises against Moderna Covid-19 vaccine for under 30s.

10 Nov, 2021 | 07:18h | UTC

French Health Authority Advises Against Moderna COVID-19 Vaccine for Under 30s – Reuters

Commentary on Twitter

France's public health authority has recommended people under 30 be given Pfizer's Comirnaty COVID-19 vaccine when available instead of Moderna Inc's Spikevax jab, which carried comparatively higher risks of heart-related problems. https://t.co/4gPTXzEsw0

— Reuters Health (@Reuters_Health) November 9, 2021

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

10 Nov, 2021 | 07:13h | UTC

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm – Science

Original viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Opinion | Protective immunity after recovery from SARS-CoV-2 infection.

10 Nov, 2021 | 07:15h | UTC

Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases

Commentary on Twitter

"Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements"
Do you agree with this?
I don't #IDtwitter https://t.co/FHbgXILD8Z

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) November 9, 2021

Practice Review: COVID-19 rapid diagnostics.

9 Nov, 2021 | 01:52h | UTC

COVID-19 rapid diagnostics: practice review – Emergency Medicine Journal

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

9 Nov, 2021 | 01:46h | UTC

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic – JAMA Internal Medicine

Author Interview: Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Results With Persistent Physical Symptoms – JAMA Internal Medicine

Commentaries: Expert reaction to study looking at the association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms – Science Media Centre

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

Except for anosmia, persistent symptoms after COVID-19 may be more related to the belief of having had #COVID19 than to actual SARS-Co-V2 infection. Clinicians and researchers should also consider general mechanisms that may not be specific to #SARSCoV2 https://t.co/IdSh5GhdQ6

— JAMA Internal Medicine (@JAMAInternalMed) November 8, 2021

How protein-based COVID vaccines could change the pandemic.

9 Nov, 2021 | 01:41h | UTC

How protein-based COVID vaccines could change the pandemic – Nature

We can be confident there have been far more than 5 million global Covid deaths – “Estimating ‘excess’ fatalities, a more robust analysis method, puts the pandemic’s grim toll between 10m and 19m people”.

9 Nov, 2021 | 01:43h | UTC

We can be confident there have been far more than 5 million global Covid deaths – The Guardian

Global Covid-19 deaths surpass five million.

Effects of the Covid-19 pandemic on life expectancy and premature mortality in 2020 – this time series analysis showed there were more than 28 million excess years of life lost in 2020 in 31 countries.

Under-reporting of deaths limits our understanding of true burden of covid-19.

Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.

Just how do deaths due to COVID-19 stack up?

Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.

9 Nov, 2021 | 01:44h | UTC

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance

Not all Covid waves look the same. Here’s a snapshot of the Delta surge.

9 Nov, 2021 | 01:28h | UTC

Not all Covid waves look the same. Here’s a snapshot of the Delta surge – STAT

Commentary on Twitter

If you know someone on the fence about vaccination, show them this https://t.co/ndPLhpLlh4 pic.twitter.com/L6RLwHyGCi

— David Juurlink (@DavidJuurlink) November 8, 2021

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.

9 Nov, 2021 | 01:31h | UTC

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines – The Conversation

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

Commentary on Twitter (thread – click for more)

Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt

— David Boulware, MD MPH (@boulware_dr) November 5, 2021